Loading organizations...
Ollin Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for severe, vision-threatening ophthalmic diseases. It advances a pipeline of differentiated drug candidates, including bispecific antibodies like OLN324 for wet age-related macular degeneration and diabetic macular edema, and OLN102 for thyroid eye disease. Its technical approach emphasizes building upon validated biologies to improve disease control and patient outcomes.
Jason Ehrlich, M.D., Ph.D., and Atul Dandekar co-founded Ollin Biosciences in 2023. They established the company based on the insight that many ophthalmic conditions are multifactorial, necessitating therapies addressing a broader biological spectrum. This led to a strategy of developing asset-centric biotherapeutics with robust operational execution and market-informed clinical development.
Ollin Biosciences targets patients suffering from serious eye conditions. The company's long-term vision is to acquire and develop best-in-disease therapies, ultimately redefining what is possible in ophthalmology. They aim to deliver meaningful improvements in treatment outcomes, advancing innovation to preserve and improve vision.
Ollin Biosciences has raised $100.0M across 1 funding round.
Ollin Biosciences has raised $100.0M in total across 1 funding round.
Ollin Biosciences has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $100M Series A | — | ARCH Venture Partners, Mubadala, Polaris Partners | Announced |
Ollin Biosciences has raised $100.0M in total across 1 funding round.
Ollin Biosciences's investors include ARCH Venture Partners, Mubadala, Polaris Partners.
Ollin Biosciences is a clinical-stage biopharmaceutical company focused on acquiring and developing best-in-class therapies for vision-threatening ophthalmic diseases, such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and thyroid eye disease (TED).[1][2][3][4] It builds an asset-centric pipeline of bispecific antibodies and novel biologics, serving patients with intractable eye conditions by targeting multiple disease pathways for improved anatomic outcomes, durability, and disease control over standards like Roche's Vabysmo and Amgen's Tepezza.[1][3][4] Backed by $100 million in initial financing from investors including ARCH Venture Partners, Mubadala Capital, and Monograph Capital, Ollin demonstrates strong growth momentum with programs like OLN324 (in Phase 1b, fully enrolled) and OLN102 in late preclinical stages, plus recent deals like the 2025 licensing of VBS-102 from VelaVigo.[2][3][4][5]
The company's approach emphasizes operational execution, market-informed strategies, advanced data science, and ophthalmic imaging to accelerate development, positioning it as an ophthalmology "development engine."[1][2]
Ollin Biosciences was established in 2023 in stealth mode, emerging publicly with its $100 million launch in late 2024 or early 2025, headquartered in Chicago, Illinois, with operations in San Diego, California, and ties to Austin, Texas.[2][3][5] Co-founder and CEO Jason Ehrlich, M.D., Ph.D., a clinician-scientist with prior roles as chief medical officer at Kodiak Sciences and leadership at Genentech, leads the effort alongside a world-class team of ophthalmology experts.[1][2][3][5] Board chair Paul Berns, managing director at ARCH Venture Partners, highlights the assembly of capital, team, and tools to advance next-generation candidates.[1][2][4]
The idea emerged from recognizing gaps in ophthalmology, where few asset-centric biotechs exist; Ollin pivots to business development for validated biologics rather than de novo discovery, gaining early traction with Innovent Biologics collaboration on OLN324 and a fully enrolled Phase 1b trial comparing it to faricimab.[1][2][4]
Ollin rides the wave of bispecific antibodies in ophthalmology, addressing limitations of single-target therapies amid rising demand for durable treatments in aging populations with AMD, DME, and TED—markets dominated by blockbusters like Vabysmo ($3B+ potential) and Tepezza.[3][4] Timing aligns with physician shifts (e.g., Eylea to Vabysmo) and biotech's shift to asset acquisition post-patent cliffs, fueled by advanced imaging/AI for precise trials.[1][2][4] Market forces favor Ollin: unmet needs in multi-pathway diseases, China partnerships (Innovent), and $100M+ war chests for milestones up to $440M.[4][5]
It influences the ecosystem by proving "development engines" can outpace big pharma in niche execution, potentially accelerating next-gen ophthalmics and inspiring similar builds.[2][4]
Ollin is primed to challenge incumbents with Phase 1b OLN324 data, VBS-102 integration, and pipeline expansion via deals, targeting 2026+ readouts that could validate superiority in potency/dosing.[3][4][5] Trends like AI-driven imaging, bispecific evolution, and orbital disease expansion (e.g., Graves') will shape its path, with funding supporting Phase 2/3 pushes.[1][3][5] Influence may grow as a serial acquirer, redefining ophthalmology biotech if it delivers on "best-in-disease" promises—echoing its launch as a purpose-built engine for intractable eye threats.[1][2]
